阿德福韦酯联合拉米夫定及单用恩替卡韦对乙肝肝硬化患者的疗效比较被引量：22

Comparison of Efficacy Difference of Adefovir Dipivoxil Combined with Lamivudine and Single Entecavir for Patients with Hepatitis B Liver Cirrhosis

在线阅读下载PDF

导出

摘要目的：研究对比阿德福韦酯联合拉米夫定及单用恩替卡韦治疗乙肝肝硬化患者的疗效差异。方法：选择2011年4月至2015年4月在我院接受治疗的乙肝肝硬化患者96例作为研究对象。根据数字随机表法将患者分成观察组以及对照组各48例,两组患者均给予常规对症治疗和支持治疗,观察组另给予拉米夫定以及阿德福韦酯治疗,对照组给予恩替卡韦治疗,两组疗程为48周,对比两组各时期乙肝病毒脱氧核糖核酸（HBV-DNA）转阴率及乙型肝炎E抗原（HBe Ag）转换率,治疗前后的总胆红素（TBIL）,白蛋白（ALB）、丙氨酸氨转换酶（ALT）及凝血酶原活动度（PTA）等指标水平,以及治疗后的不良反应。结果：两组4-48周后的HBV-DNA转阴率及HBe Ag转换率对比,差异均无统计学意义（均P〉0.05）。组内比较,两组治疗后的TBIL及ALT水平均显著低于治疗前,PTA水平显著高于治疗前,差异有统计学意义（P〈0.05）。观察组治疗后的不良反应发生率是16.67%（8/48）,与对照组的18.75%（9/48）对比,差异无统计学意义（P〉0.05）。结论：阿德福韦酯联合拉米夫定对乙肝肝硬化患者具有较好的疗效,且安全性较高,值得在临床上推广应用。 Objective： To cstudy and ompare the efficacy difference of Adefovir dipivoxil combinated with lamivudine and single entecavir for patients with hepatitis B liver cirrhosis. Method： 96 cases from April2011 to April 2015 in our hospital for treatment of hepatitis B cirrhosis were selected as the research objects.According to the random number table method,the patients were divided into two groups： observation group and control group,with 48 cases in each group. Both groups of patients were given conventional symptomatic and supportive treatment. The observation group was given lamivudine and adefovir dipivoxil for treatment,and the control group was treated by entecavir. The course of treatment in both groups was 48 weeks,and then a comparison was made between the two groups about negative rate of HBV-DNA and HBe Ag conversion rate in differect periods,the levels of TBIL,ALB,ALT and PTA between before and after treatment,and adverse reactions after treatment. Result： The difference in the negative rate of HBV-DNA and HBe Ag conversion rate between the two groups was not statistically significant（ P〈0. 05）. After treatment,the levels of ALT and TBIL in the two groups were much lower than those before treatment,and PTA levels were greatly higher than that before treatment（ P〈0. 05）,the differences were statistically significant. The incidence of adverse reactions in the observation group was 16. 67%（ 8 /48）,compared with 18. 75%（ 9 /48） in the control group,the difference was not statistically significant（ P〈0. 05）. Conclusion： Adefovir and lamivudine showed better curative effects and higher safety in the treatment of liver cimhosis. It is worth of popularization in clinical application.

作者彭思璐罗云波刘冰徐东伟

机构地区四川省绵阳中央民族大学医院

出处《河北医学》 CAS 2016年第3期355-358,共4页 Hebei Medicine

基金国家自然科学基金资助项目 (编号:81473424)

关键词阿德福韦酯拉米夫定单用恩替卡韦乙肝肝硬化 Adefovir dipivoxil Lamivudine Single entecavir Hepatitis B liver cirrhosis Efficacy difference

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献6

1汤茂刚.阿德福韦酯联合拉米夫定治疗失代偿性乙型肝炎肝硬化患者的疗效观察[J].中华传染病杂志,2011,39(8):500-502. 被引量：20
2Woo HY, Choi JY, Yoon SK,et al.Rescue therapy with ade- fovir in decompensated liver cirrhosis patients with iamivudi- ne-resistant hepatitis B virus [ J ] .Clin Mol Hepatol,2014,20 (2) :168- 176.
3范敏,兰武华,杨庆霞,孙文峰,金丽红,胡建学.耐阿德福韦酯乙肝肝硬化的治疗研究[J].中华全科医学,2010,8(12):1539-1540. 被引量：9
4Liu L, Yan Y, Zhou J, et al. Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on decompensated hepatitis B cirrhosis [ J ]. Genet Mol Res, 2014,13(4) :9336-9342.
5Wang H, Ji YY, Yao GB,et al.Two years efficiency of lami- vudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients [ J l-Eur Rev Med Pharmacol Sei, 2013, 17(5) :636-643.
6Zhong JH, Li le Q, Wu LC ,et al.Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma [J]. Cochrane Database Syst Rev, 2011, 7 (12) : 8713 - 8715.